Reduced Apaf-1 expression in human cutaneous melanomas

British Journal of Cancer

Volumn 91, Issue 6, 2004, Pages 1089-1095

  Dai, D L ^a   Martinka, M ^a   Bush, J A ^a   Li, G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

Apaf 1; Gene expression; Melanoma; Tissue microarray

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; APAF1 GENE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENDER; GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SKIN BIOPSY; SKIN CANCER; SKIN METASTASIS; STATISTICAL SIGNIFICANCE; TECHNOLOGY; TUMOR VOLUME; ULCER;

APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEVUS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEINS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 5044237664     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602092     Document Type: Article

References (43)

1. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK (1994) Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4: 35-45
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reinigen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648
3. Baldi A, Santini D, Russo P, Catricala C, Amantea A, Picardo M, Tatangelo F, Botti G, Dragonetti E, Murace R, Tonini G, Natali PG, Baldi F, Paggi MG (2004) Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 13: 93-97
4. Bush JA, Cheung Jr KJ, Li G (2001) Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 271: 305-314
5. Bush JA, Li G (2003) The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 20: 531-539
6. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, Martinka M, Li G (2003) Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9: 4409-4414
7. Dhawan P, Singh AB, Ellis DL, Richmond A (2002) Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62: 7335-7342
8. Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene 22: 9030-9040
9. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS (2004) Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 64: 2245-2250
10. Gilchrest BA, Eller MS, Geller AC, Yaar M (1999) The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 340: 1341-1348
11. Glass AG, Hoover RN (1989) The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 262: 2097-2100
12. Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ (1997) Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 115: 185-193
13. Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N, Frati L, Agliano AM (2003) Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 21: 306-312
14. Grossman D, McNiff JM, Li F, Altieri DC (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113: 1076-1081
15. Hakansson A, Gustafsson B, Abdiu A, Krysander L, Hakansson L (2003) Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy. Cancer Immunol Immunother 52: 249-254
16. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
17. Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, Wolff K, Pehamberger H, Jansen B (2002) Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 99: 29-34
18. Houghton AN, Polsky D (2002) Focus on melanoma. Cancer Cell 2: 275-278
19. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4: 232-234
20. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics. CA Cancer J Clin 52: 23-47
21. Jia L, Srinivasula SM, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM (2001) Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 98: 414-421
22. Koh HK, Geller AC (1995) Melanoma control in the United States: current status. Recent Results Cancer Res 139: 215-224
23. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G (2000) Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 292: 225-232
24. Li G, Bush JA, Ho VC (2000) p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 114: 514-519
25. Li G, Tang L, Zhou X, Tron V, Ho V (1998) Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 8: 17-23
26. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489
27. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nunez G (2002) Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 62: 924-931
28. Li Y, McClay EF (2002) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29: 413-426
29. Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS (2000) Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 88: 589-595
30. Montano X, Shamsher M, Whitehead P, Dawson K, Newton J (1994) Analysis of p53 in human cutaneous melanoma cell lines. Oncogene 9: 1455-1459
31. Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10: 431-442
32. Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK (2002) Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res 12: 453-463
33. Rigel DS (2002) The effect of sunscreen on melanoma risk. Dermatol Clin 20: 601-606
34. Rigel DS, Friedman RJ, Kopf AW (1996) The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 34: 839-847
35. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211
36. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogens 22: 3138-3151
37. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP (2003) Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 63: 2881-2890
38. Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Gunsberg P, Polterauer P, Pehamberger H, Monia BP, Selzer E, Wolff K, Jansen B (2003) Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120: 1081-1086
39. Tsao H, Mihm Jr MC, Sheehan C (2003) PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 49: 865-872
40. Utikal J, Leiter U, Udart M, Kaskel P, Peter RU, Krahn GM (2002) Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma. Cancer Invest 20: 914-921
41. Vihinen PP, Pyrhonen SO, Kahari VM (2003) New prognostic factors and developing therapy of cutaneous melanoma. Ann Med 35: 66-78
42. Wolf BB, Schuler M, Li W, Eggers-Sedlet B, Lee W, Tailor P, Fitzgerald P, Mills GB, Green DR (2001) Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 276: 33244-33251
43. Yamamoto H, Gil J, Schwartz Jr S, Perucho M (2000) Frameshift mutations in Fas, Apaf-1, and Bel-10 in gastro-intestinal cancer of the microsatellite mutator phenotype. Cell Death Differ 7: 238-239